Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (U01 Clinical Trial Optional)
Key Information
Due Date: February 21, 2025
Agency: U.S. Department of Health and Human Services (HHS)
Source: Federal
Funding Category:
Health & Human Services
Funding Amount: $581,371
Funding Type: Cooperative Agreement, Government
Match Required: No
Contact Info:
grantsinfo@nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Overview
The primary objective of this initiative is to establish robust research programs to explore the interplay of various factors leading to diverse disease risk phenotypes and responses to prevention or therapy in AD and ADRD. These factors include genes, environmental factors, and host-specific facets such as hormonal status, both gonadal and brain-derived. The research should scrutinize these interactions at varying levels of biological complexity - cell, tissue, organs/organ systems, and population.
The project's title is 'Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment,' and it provides an opportunity for a clinical trial.
Key Dates
Open Date: January 10, 2023
Application Due Date: February 21, 2025
Estimated Award Date: Not Specified
Additional Details
Eligible Activities
- Research and Development
Eligible Applicants
- State governments
- County governments
- City, village or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Private institutions of higher education
- Small businesses